drugset
drugset / Trial / NCT05190523

Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis

NCT05190523 ↗

Phase 2 Completed 98 enrolled Gannex Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a phase II, multicenter, randomized, double-blind, placebo-controlled, seamless adaptive design clinical study, aiming to evaluate the safety and effectiveness of three doses of ASC42 matched placebo in subjects with primary biliary cholangitis.

Timeline

Start
2022-04-06
Primary completion
2024-03-13
Completion
2024-03-13

Drugs

EvaluationDrugModalityDoseRoute
Subject ASC42 Unknown 5 mg Oral
Subject ASC42 Unknown 10 mg Oral
Subject ASC42 Unknown 15 mg Oral

Indications

primary biliary cholangitis